Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of
patients with primary progressive or secondary progressive multiple sclerosis without
relapse.